← Leaderboards
John H Yim
Beckman Research Institute/City Of Hope
$2,703,313
Attributed
$4,746,475
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2005–25$2M$1.5M$1M$500K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,746,475 · 3
By mechanism
R01$3,647,565 · 1
K08$660,150 · 1
R21$438,760 · 1
Top collaborators
- Maria Hahn7 shared
Most similar at Beckman Research Institute/City Of Hope
Same institution · by research overlap
- Maria Hahn$2,043,163
- Anna M Wu$10,747,779
Others in their field
Top investigators on “Malignant Neoplasms”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,074,554,219
- Leonard Freedman · Leidos Biomedical Research, Inc.$527,106,485
- Ethan Dmitrovsky · Leidos Biomedical Research, Inc.$357,875,933
- Richard K. Wilson · Washington University$274,272,747
- Larry Arthur$223,443,122
- Lynn Briscoe · Leidos Biomedical Research, Inc.$186,892,879
Research focus
Malignant NeoplasmsUnited StatesBiologicalEpigenetic ProcessMalignant - DescriptorCancer DiagnosticsValidationSurgeonThyroid NoduleBiological MarkersMolecular DiagnosticsDiagnosticNoduleMalignant Neoplasm Of ThyroidThyroid GlandEpigenomicsDna MethylationBenignBilateralCancer RiskDiagnostic AccuracyEvaluationGene FusionCytopathology
Grant awards (12)
Validation of epigenomic biomarkers for thyroid cancer diagnostics$819,119
R01 · FY2025 · CA
Validation of epigenomic biomarkers for thyroid cancer diagnostics$779,408
R01 · FY2024 · CA
Validation of Epigenomic Biomarkers for Thyroid Cancer Diagnostics$267,000
R01 · FY2024 · CA
Validation of epigenomic biomarkers for thyroid cancer diagnostics$823,929
R01 · FY2023 · CA
Validation of epigenomic biomarkers for thyroid cancer diagnostics$958,109
R01 · FY2021 · CA
Epigenomic Biomarkers to Manage Thyroid Nodule Overdiagnosis and Overtreatment$196,127
R21 · FY2019 · CA
Epigenomic Biomarkers to Manage Thyroid Nodule Overdiagnosis and Overtreatment$242,633
R21 · FY2018 · CA
Role of IRF-1 in Tumor Suppression of Breast Cancer$132,030
K08 · FY2008 · CA · contact PI
Role of IRF-1 in Tumor Suppression of Breast Cancer$132,030
K08 · FY2007 · CA · contact PI
Role of IRF-1 in Tumor Suppression of Breast Cancer$132,030
K08 · FY2006 · CA · contact PI
Role of IRF-1 in Tumor Suppression of Breast Cancer$132,030
K08 · FY2005 · CA
Role of IRF-1 in Tumor Suppression of Breast Cancer$132,030
K08 · FY2004 · CA